Company Interview / Biome Australia (BIO) pitched by Canary Capital

Blair from Biome Australia states that probiotics are not typical supplements, pointing to their evidence-backed success from clinical trials. The company stands out with condition-specific probiotics that target diseases, launching the concept in 2019 with significant results in trials for conditions like pediatric allergic asthma. They're expanding globally, starting with markets like the UK, Ireland, and Canada.

Speaking on the company's growth plans, Blair reveals that Biome Australia has seen significant financial accomplishments since its listing in 2021, achieving cash flow positivity and significant revenue growth. They aim to penetrate Australia's pharmacy market further while expanding internationally, offering a unique strategy in diverse markets.

Paul Hart from Canary Capital highlights Biome Australia's robust position supported by exclusive strains and research-backed products. He sees the company's potential for substantial profitability and recognises its ambitious plans as compelling reasons to invest. He also says the company's unique in range of 18 condition-specific probiotics, backed by clinical research, shows that they actually work give the company their MOAT.